Too much emphasis on the risks of gain-of-function may hold back important resea...
The Phase II trial for Zynlonta and Rituxan in DLBCL patients was discontinued a...
Johnson & Johnson (J&J) has reported sales of $25.53bn in Q2 of 2023, indicating...
Biotechnology firm EpiBiologics has appointed Dr Ann Lee-Karlon as CEO, presiden...
The US FDA has granted approval for Daiichi Sankyo’s Vanflyta to treat adults wi...
The FDA grants SN Bioscience’s nano-therapy SNB-101 an orphan drug designation f...
Other forms of immunotherapy have progressed rapidly in recent years, but oncoly...
To reduce cash burn, the company has sold off its Asia Pacific operations, excep...
Janssen has plans to discontinue the CD388 influenza programme as part of pipeli...
While artificial intelligence (AI) in medical devices has regulatory boundaries,...
In the global pharmaceutical industry, there were 7 private equity deals announc...
A new review finds that private equity ownership generally means higher costs fo...
Sen. Bernie Sanders wants to do away with drug patents and other IP protections ...
What can Homer teach us about biotech? Has Big Science gotten too big? And what'...
In the latest edition of STAT's Health Tech newsletter: priming doctors for GPT-...
Marc Tessier-Lavigne's abrupt departure as Stanford's president after a research...
